ArticleLiver research (Beijing, China)2022

Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases.

Tianxing Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.